`
The Europe handheld echocardiography devices market was valued at USD 11.6 million in 2022 and is projected to grow from USD 12.7 million in 2023 to USD 26.2 million by 2030, exhibiting a CAGR of 10.9% during the forecast period (2023–2030). This growth is primarily driven by the rising prevalence of cardiovascular diseases, the increasing adoption of portable diagnostic tools, and the cost-effectiveness of handheld devices compared to conventional echocardiography systems.
Handheld echocardiography devices are non-invasive tools that enable cardiologists to screen and diagnose heart conditions efficiently. These devices can transform mobile phones or tablets into ultrasound systems via a transducer, either plugged in or connected wirelessly. Their compact size and affordability have made them particularly valuable in intensive care units (ICUs), cardiology clinics, and point-of-care settings.
COVID-19 Impact
The market experienced a slowdown in 2020 due to pandemic-related restrictions that reduced patient hospital visits and non-emergency diagnostic procedures. According to data from the British Heart Foundation, only 87,902 echocardiograms were conducted in England during May and June 2020 — a decline of nearly 68% compared to the same period the prior year.
However, handheld devices found renewed relevance during the pandemic for monitoring heart function in COVID-19 patients in ICUs. Post-pandemic recovery saw key players such as Koninklijke Philips N.V. regain momentum in their ultrasound revenue streams in 2021 and 2022.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/europe-handheld-echocardiography-devices-market-108884
Key Market Trends
Telehealth Integration: A major trend shaping the market is the convergence of ultrasound technology with telehealth platforms. Companies like GE HealthCare, Clarius, and Butterfly Network, Inc. have launched telemedicine platforms — including Butterfly Teleguidance and Clarius Live — that enable remote guidance during ultrasound procedures. This is especially valuable for training new practitioners and enabling remote expert consultations.
Market Segmentation
By Test Type
- Transthoracic Echocardiography held the dominant share in 2022. The rising prevalence of atrial fibrillation — affecting around 9.0 million Europeans aged 55+ in 2020 (projected to reach 14.0 million by 2060, per the American Heart Association) — is a key growth driver.
- Others (including fetal and transesophageal echocardiography) are expected to grow at a significant CAGR as handheld devices gain traction in gynecology clinics for fetal diagnostics.
By Technology
- 2D Imaging held a significant share in 2022, driven by manufacturers' focus on advancing hemodynamic measurement capabilities (e.g., Philips Lumify).
- Doppler Imaging is projected to grow at the fastest CAGR, supported by its high clinical accuracy in detecting cardiovascular lesions.
By End-User
- Hospitals & ASCs led the market in 2022, fueled by widespread ICU adoption.
- Diagnostic Centers are expected to see substantial growth, supported by the expanding number of EACVI Echo Accredited Laboratories across Europe (100+).
Regional Insights
Germany generated the highest market value of USD 2.8 million in 2022, driven by a large patient population with coronary heart disease and stroke history. The United Kingdom is expected to grow at a significant CAGR, supported by a government commitment to establishing 160 community diagnostic centers in England by 2025 and a healthcare investment of approximately USD 42.5 billion in the health and social care system.
Competitive Landscape
The market is led by a concentrated group of key players:
- GE Healthcare — dominant through acquisitions, including Caption Health, Inc. in February 2023 to expand affordable ultrasound access.
- Koninklijke Philips N.V. — strong European presence across Germany, France, Italy, Spain, and the U.K.
- Butterfly Network, Inc. — known for its AI-driven handheld ultrasound platform.
- Clarius — active in R&D and partnerships; launched the Clarius Power Fan HD3 in January 2023.
- Others include EchoNous Inc., CHISON Medical Technologies, and ImaCor.
Restraining Factors
Despite strong growth prospects, the market faces challenges including the absence of 3D/4D imaging in handheld devices, comparatively lower image quality than cart-based systems, a shortage of experienced sonographers, and limited awareness in emerging European markets.
Conclusion
Europe's handheld echocardiography market presents strong and sustained growth potential through 2030, driven by cardiovascular disease burden, digital health integration, and government investment in diagnostic infrastructure. As technology advances and telemedicine adoption grows, handheld echocardiography is poised to become a standard tool in cardiac care across European healthcare settings.
`
Top comments (0)